JP2021531280A5 - - Google Patents

Info

Publication number
JP2021531280A5
JP2021531280A5 JP2021502704A JP2021502704A JP2021531280A5 JP 2021531280 A5 JP2021531280 A5 JP 2021531280A5 JP 2021502704 A JP2021502704 A JP 2021502704A JP 2021502704 A JP2021502704 A JP 2021502704A JP 2021531280 A5 JP2021531280 A5 JP 2021531280A5
Authority
JP
Japan
Prior art keywords
protein
marker
disease
glial cell
manipulated
Prior art date
Application number
JP2021502704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531280A (ja
JPWO2019190879A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023395 external-priority patent/WO2019190879A1/en
Publication of JP2021531280A publication Critical patent/JP2021531280A/ja
Publication of JP2021531280A5 publication Critical patent/JP2021531280A5/ja
Publication of JPWO2019190879A5 publication Critical patent/JPWO2019190879A5/ja
Priority to JP2024063938A priority Critical patent/JP7697096B2/ja
Priority to JP2025097962A priority patent/JP2025123315A/ja
Pending legal-status Critical Current

Links

JP2021502704A 2018-03-27 2019-03-21 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 Pending JP2021531280A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024063938A JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648684P 2018-03-27 2018-03-27
US62/648,684 2018-03-27
PCT/US2019/023395 WO2019190879A1 (en) 2018-03-27 2019-03-21 Car-treg-based therapies for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063938A Division JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Publications (3)

Publication Number Publication Date
JP2021531280A JP2021531280A (ja) 2021-11-18
JP2021531280A5 true JP2021531280A5 (https=) 2022-03-24
JPWO2019190879A5 JPWO2019190879A5 (https=) 2022-03-24

Family

ID=68060734

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021502704A Pending JP2021531280A (ja) 2018-03-27 2019-03-21 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療
JP2024063938A Active JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024063938A Active JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Country Status (7)

Country Link
US (2) US12173030B2 (https=)
EP (1) EP3773629A4 (https=)
JP (3) JP2021531280A (https=)
KR (2) KR102892999B1 (https=)
CN (1) CN112867496B (https=)
AU (1) AU2019242381B2 (https=)
WO (1) WO2019190879A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867496B (zh) * 2018-03-27 2026-03-17 阿尔茨治疗方法公司 用于治疗神经退行性疾病的基于car-treg的疗法
JP7821119B2 (ja) 2020-04-23 2026-02-26 エーゼットセラピーズ， インコーポレイテッド Ｈｌａクラスｉ ｍｈｃの細胞切除
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
EP4396216A1 (en) * 2021-09-03 2024-07-10 Sangamo Therapeutics, Inc. Mog-binding proteins and uses thereof
TW202321286A (zh) * 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
US20080027001A1 (en) 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
SG193023A1 (en) * 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
KR20140071277A (ko) 2011-05-19 2014-06-11 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
SG10202013095YA (en) * 2014-12-30 2021-02-25 Brigham & Womens Hospital Inc Methods to improve cell therapy
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
CN107708733B (zh) * 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
WO2017100428A1 (en) * 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
EP4321649B1 (en) * 2017-11-11 2025-08-20 Micromaterials LLC Gas delivery system for high pressure processing chamber
CN112867496B (zh) * 2018-03-27 2026-03-17 阿尔茨治疗方法公司 用于治疗神经退行性疾病的基于car-treg的疗法
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases

Similar Documents

Publication Publication Date Title
JP2021531280A5 (https=)
US12296025B2 (en) AAV capsid variants and uses thereof
Ford et al. Human pluripotent stem cells-based therapies for neurodegenerative diseases: current status and challenges
Huebner et al. Axon regeneration in the peripheral and central nervous systems
Huang et al. Engineered basic fibroblast growth factor-overexpressing human umbilical cord-derived mesenchymal stem cells improve the proliferation and neuronal differentiation of endogenous neural stem cells and functional recovery of spinal cord injury by activating the PI3K-Akt-GSK-3β signaling pathway
Dantuma et al. Stem cells for the treatment of neurodegenerative diseases
MD3672614T2 (ro) Vezicule extracelulare modificate și utilizări ale acestora
MA33609B1 (fr) Molecules de liaison a dll4
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
JP2017502920A5 (https=)
JP2014520148A (ja) 治療のための神経筋接合部への標的化
JPWO2019190879A5 (https=)
JP2022512749A (ja) Ｌｒｉｇ－１タンパク質に特異的な結合分子及びその用途
MA35233B1 (fr) Molecules de liaison bispecifiques se liant à dii4 et ang2
JP2020072685A (ja) クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体
Gozes et al. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide)
KR20210038841A (ko) 게놈 편집을 위한 방법 및 조성물
US20180111991A1 (en) Modulators of activin and methods for modulating immune responses and t follicular helper cells
CN121488045A (zh) Aav衣壳变体及其用途
CA3110309A1 (en) Treating spinal cord injury (sci) and brain injury using gsx1
JP2021534206A5 (https=)
WO2011057144A2 (en) Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
Tuinstra et al. Gene delivery to overcome astrocyte inhibition of axonal growth: An in vitro Model of the glial scar
JPWO2021243275A5 (https=)